Key Highlights

  • Enveric Biosciences released fresh GloSensor cAMP assay findings for EB-003.
  • The new data is consistent with previous BRET data.
  • The findings further validate the non-hallucinogenic preclinical profile of EB-003.
  • The company continues to progress the candidate toward Phase 1 clinical entry.

Enveric Biosciences (NASDAQ: ENVB) released fresh GloSensor cAMP assay findings consistent with previous BRET data, further validating the non-hallucinogenic preclinical profile of its EB-003 candidate.

What Happened

The firm continues to progress its neuroplastogenic small molecule candidate as it prepares for Phase 1 clinical entry targeting neurological and psychiatric conditions.

Market Reaction

The disclosed information does not include stock price or trading data for Enveric Biosciences following the assay data release.

Outlook

Progress toward Phase 1 clinical entry for EB-003 represents the next disclosed milestone for the program targeting neurological and psychiatric conditions.

What new data did Enveric Biosciences release?

Fresh GloSensor cAMP assay findings for EB-003, consistent with previous BRET data.

What does this data validate?

The non-hallucinogenic preclinical profile of EB-003.

What is the next step for EB-003?

Preparation for Phase 1 clinical entry targeting neurological and psychiatric conditions.